Good morning. My name is Laurie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Viatris First Quarter 2021 Earnings Call and Webcast. All participants’ lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. Thank you. I will now like to turn the call over to Melissa Trombetta, Head of Global Investor Relations. Please go ahead.

Thank you, Laurie. Good morning, everyone. Welcome to Viatris’ first quarter 2021 earnings conference call. Joining me on this call are Viatris’ Chief Executive Officer, Michael Goettler; President, Rajiv Malik; Chief Financial Officer, Sanjeev Narula; Chief Accounting Officer and Controller, Paul Campbell; and Bill Szablewski, Head of Capital Markets. While some of us are in remote locations, I would ask for your patience should we encounter any technical difficulties. During today’s call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2021. These forward-looking statements are subject to risks and uncertainties that could cause future results or events to differ materially from today’s projections. Please refer to the earnings release that we furnished to the SEC on Form 8-K earlier today for a fuller explanation of those risks and uncertainties and the limits applicable to forward-looking statements. We also posted supplemental slides on our website at investor.viatris.com. Viatris routinely posts information that may be important to investors on this website, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of SEC’s regulation fair disclosure. We also will be referring to certain non-GAAP financial measures including free cash flow and adjusted EBITDA. We will reference such measures in order to supplement your understanding and assessment of our first quarter 2021 financial results and financial guidance for 2021. Non-GAAP measures should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP. The most directly comparable GAAP measures as well as reconciliations of the non-GAAP measures to those GAAP measures are available in our first quarter 2021 earnings release and supplemental earnings slides as well as in the Investors section of our website. In addition, solely to supplement your understanding and assessment of our first quarter 2021 financial performance, we have provided in our earnings release and supplemental slides, and we’ll discuss during today’s call certain financial measures relating to the first quarter of 2020, including combined results of legacy Mylan and the Upjohn business with indicated adjustments, which do not reflect pro forma results in accordance with ASC 805 or Article 11 of Regulation S-X. Such measures do not reflect the effect of any purchase accounting adjustments. Let me also remind you that the information discussed during this call, except for the participant questions, is the property of Viatris and cannot be recorded or rebroadcast without Viatris’ express written permission. An archived copy of today’s call will be available on our website and will remain available for a limited time. With that, I’d like to turn the call over to Michael.

Thank you, Melissa, and good morning, and thanks for joining us for our first quarterly earnings call as Viatris. I’m pleased to say that we’re off to a strong start with high quality first quarter results across the board. And this strong performance comes at a time when the COVID-19 global pandemic continues to evolve, taking different courses across the many geographies in which Viatris operates. We’re grateful to our colleagues around the world who continue to put patients first, ensuring stable access to needed medicines, particularly in India and parts of Latin America, where significant resurgence has impacted our teams there. The health and safety of our colleagues and their families is our highest priority. And we’re supporting the continually evolving situation around the globe with urgency, care, and compassion. For our patients, we’re working diligently to bring the medicines they need, including ramping up the production of the antiviral medicine remdesivir in India and closely partnering with the government to ensure access to this critical medicine. Back when we launched Viatris in November 2020, our vision was to build a new kind of healthcare company, differentiated by a global operating platform with significant scale and commercial capabilities and expertise across science, manufacturing, legal, and IP. A broad, diverse product portfolio that includes brands, complex generics, biosimilars, and generics, and is agnostic to therapeutic categories, dosage forms, and delivery mechanisms, and a strong R&D platform that is well positioned to deliver a broad pipeline of complex and novel products, including late-stage biosimilar programs. Our strong first quarter results validate the success of a diversified and robust business that can absorb headwinds in any individual part of the business while seizing market opportunities where and when they present themselves. In the first quarter, we reported net sales of $4.4 billion, adjusted EBITDA of $1.6 billion, and free cash flow of $799 million, which were above our original expectations. These results reflect the strength of our business and were also partially helped by favorable timing of some revenue and expenses, and by favorable FX. Now, let me give you some key highlights for the quarter. The strength of our business was driven by solid performance across all four of our commercial segments: Developed Markets, Greater China, Emerging Markets, and JANZ, which is Japan, Australia, and New Zealand. Excluding the effects of loss of exclusivity of Lyrica in Japan and Celebrex in Japan this quarter, we would have reported 3% growth on the actual exchange rate basis, or a 2% decline on a constant currency basis, as compared to the combined LOE adjusted quarter one 2020 results. Lyrica Japan is our last major LOE, and we see no further significant LOEs impacting our business in the coming years. This quarter, we generated $163 million in new product revenue to partially offset inherent product erosion. We’re on track to achieve $690 million in new product revenue for the full year. We’re continuing to shift to a more differentiated and sustainable portfolio with strong growth in Complex Generics and Biosimilars, and growth in our recently acquired Thrombosis franchise in Europe. Regarding our pipeline, this quarter, we received notable approvals in Europe for Insulin Aspart and Bevacizumab, and we made significant progress on many key pipeline projects which Rajiv will discuss later in more detail. With regard to the integration of our two legacy companies, we are pleased to say our plans are progressing smoothly. This quarter, I also had the opportunity to meet remotely with hundreds of colleagues around the world, and I continue to be impressed with the talent, the passion, and the engagement that we have at Viatris. We are well on our way to forming as one team and making our performance-driven, highly engaging and inclusive culture a reality. For our shareholders, we’re delivering our commitments. The Viatris Board has declared an overall quarterly dividend of $0.11 a share consistent with 25% of the midpoint of the 2021 full year free cash flow guidance. We are on track to achieve $500 million in synergies this year. We are on plan and continue to target $6.5 billion in debt repayment by 2023. We’re reporting our first quarter results with the enhanced disclosures and transparency that we previously committed to. We’re also aware of the interest by our shareholders in the sustainability of our business and our commitment to corporate social responsibility. Sustainability is fundamental to our mission and embedded in everything we do. And I’m pleased to share that we published our inaugural Sustainability Report as Viatris. More details on that can be found on our website, including a deeper look at Viatris’ role in the important fight against COVID-19. In closing, we’re proud to report a very strong and high-quality first quarter. We’re seeing underlying strengths in our business, and we are reaffirming our full year financial guidance for 2021, which incorporates the known potential headwinds and tailwinds for the remainder of the year. At the conclusion of the second quarter, we will be reassessing whether to update guidance for the full year. While we’re not giving long-term guidance at this time, we continue to feel strongly that 2021 is our trough year as defined by the midpoint of our guidance of $6.2 billion adjusted EBITDA. We believe that $6.2 billion is the true floor of our business, not just for this year, but also for future years. Now with that, let me turn it over to Rajiv to give you more details about our segment results, pipeline progress, and restructuring integration efforts.

Thank you, Michael, and good morning everyone. I would like to say hello to our employees around the world and thank them for all of their hard work and commitment to Viatris. I would especially like to recognize my colleagues and friends in India and express my deepest sympathies to everyone who is enduring a very difficult situation as the pandemic resurges in parts of the world. Earlier this year, we shared with you our approach to execute our 2021 plan: minimizing the base business erosion, executing new launches, and integrating and synergizing. I’m very pleased to inform you that we are off to a great start. I’ll be making certain comparisons to combined LOE adjusted quarter one 2020 results on a constant currency basis, as well as comparisons versus our expectations as included in our full year guidance. Beginning on Slide 10, our business performed better than expectations but was down 2% in this quarter as compared to combined LOE adjusted quarter one 2020 results. Our brand business performed better than our expectations, driven by products such as EpiPen, Amitiza, Lipitor, and Viagra. Our Complex Generics and Biosimilars business grew by 27%, largely driven by biosimilars. And our global generics business performed in line with our expectations. We delivered $163 million for the new launches and remain on track to meet our $690 million targets for the year. We continue to expect normalized based business erosion of 3% to 4% for the year. Our Developed Markets segment performed better than our expectations this quarter. Our brand portfolio performance was driven by higher EpiPen in the U.S., largely due to vaccination-related buying. Yupelri, our first nebulized LAMA, performed in line with our expectations, and we are well positioned to expand this market. Our European brand business was helped by Creon, Dymista, as well as our Thrombosis portfolio, acquired from Aspen, highlighting our ability to effectively manage our portfolio of established brands. Our Complex Generics and Biosimilars portfolio grew by 27% in developed markets, largely driven by pegfilgrastim, trastuzumab, and adalimumab biosimilars. Our generics portfolio performed in line with our expectations once adjusted for COVID surge buying in the first quarter of 2020, which accounts for half of the year-over-year decline. I would like to provide a bit more color around our U.S. generics business, which is approximately 11% of our total business now. Our current generics portfolio is now a combination of diversified product forms, including extended release oral solids, injectables, transformers, and topicals. We implemented our disciplined approach to resource allocation and portfolio management, including the rationalization of negative margin products. We believe that extending this approach to our overall business will help us manage our base business more effectively. Looking ahead, we have assumed increased competition for our complex products like Xulane, Wixela, glatiramer acetate, in addition to the loss of exclusivity of performance. Moving to the next slide, our Emerging Markets segment performed in line with expectations. Our business was affected by the negative impact of COVID on our lifestyle brands, as well as a one-time impact of change in go-to-market strategy in Vietnam. We see our Complex Generics and Biosimilars business growing over the year, driven by a number of new launches in multiple countries. Our generic business was roughly flat and in line with expectations. Our JANZ segment grew 14% as we adjusted for one-time Lyrica and Celebrex LOEs. Our brand portfolio in Japan had strong performance driven by Amitiza, Lipitor, and Creon. Lyrica LOE is performing to our expectations. We also launched the first adalimumab biosimilar in Japan. Our generic business performed strongly. Now, to Slide 14, our Greater China segment performed strongly and grew by 9%. This was primarily driven by 30% growth in our retail channel, better-than-expected hospital channel performance, as well as the benefits from the COVID recovery. Our retail channel now represents 40% of our China business. We have assumed the full impact of VBP for 2021, as well as mid-year implementation of URP in certain regions. As already mentioned, on our guidance call, the trough of our China business will be determined by the timing of the full implementation of URP. We see continued momentum, and we look forward to investing in our pipeline in this region. Out of 25 products we identified for Greater China, we are well positioned to file six regulatory submissions in 2021. Now, switching to providing more details around the impact of COVID-19. India is currently going through its worst pandemic phase, and we are doing everything possible to protect the health and safety of our employees in India. We are also working closely with health authorities to maintain the supply of remdesivir. We have a broad, diverse, and resilient global manufacturing and supply chain footprint. We are not depending on any one country or site. Even in India, our manufacturing footprint is spread over five different states, which mitigates the risk of disruption in any given part of the country. As Viatris, our reliance on India as a supply hub has relatively come down as compared to legacy Mylan. The diversity of our network helped us achieve an approximately 95% customer service level across the globe last year. We are continuously monitoring our inventories and currently are in a strong position from a supply point of view to meet our customer needs across the globe. I would now like to share some key updates on our pipeline shared with you on Investor Day. I’ll start with our biosimilars franchise on Slide 17. Our 351(k) Insulin Aspart for interchangeability is on track for a July FDA goal date. Our insulin aspart is also tracking towards its FDA goal date in July and is expected to include interchangeability. We are making steady progress for our biosimilar to Botox, and recently submitted our briefing package to the FDA for agreement on Phase 3. We have just received top-line results for our clinical Phase 3 study for our biosimilar to Eylea, and are pleased to report that we have met the primary endpoint for this study. We received European approval for the biosimilar to Avastin and Insulin Aspart. While we no longer have any open scientific questions with the FDA, our U.S. approval of biosimilar to Avastin has been impacted by the delay in a pre-approval inspection due to COVID travel restrictions. The next slide shows our complex product pipeline. For our glatiramer acetate once-monthly, we have dosed more than 900 patients and are on track for our submission at the end of 2022. We also achieved positive results in Phase 2 trial for meloxicam, which was designed as a proof-of-concept study for a quicker onset of acute pain relief as an alternative to opioids. We are excited that we have advanced a new low-dose formulation of Xulane, which we formerly called MR-100. We are expecting this product to be one of the smallest low-dose patches in its class, and our Phase 3 clinical trials have been initiated. The next slide shows our continued progress in our complex injectable pipeline. Our octreotide MR Injection clinical study is well underway to support our U.S. submission. Clinical study for EU Trinza are on track for quarter two 2021. We are also in the process of initiating clinical studies for amphotericin B, previously called MR-118. I’ll finish with an update on our integration and restructuring program. As you can see on Slide 21, we remain on track to realize $500 million of cost synergies this year. Our workforce actions are well underway, including a recently announced voluntary retirement program in Japan, which is on schedule. As we announced earlier this year, the rationalization of 13 manufacturing sites have been identified, and closure or divestiture activities are in process. We are working very closely with regulators and our customers to avoid any supply disruptions, and are building appropriate safety stocks. With all of these actions underway, we remain confident that we will exceed our target of $1 billion in cumulative cost savings by 2023. Let me now turn the call over to Sanjeev. Thank you.

Thank you, and good morning, everyone. As Michael and Rajiv mentioned, we’re off to a strong start, and I’ll walk you through the key drivers and how we see certain trends shaping up for the rest of the year. As you will see in the coming slides, I’ll make comparisons to prior year Mylan standalone combined adjusted results as well as our 2021 expectations. On Slide 23, we have summarized our results versus the prior year on a reported basis, which reflects Mylan standalone results for quarter one, 2020. Adjusted gross margin and adjusted EBITDA benefited from contributions of Upjohn branded products and the strength of China, which was driven by stable sales in the hospital business and retail growth, including COVID recovery. In total, these factors led to a significant increase in financial strength, including profitability and cash flow generation. Moving to Slide 24, I have highlighted the drivers in the quarter compared to combined adjusted Q1, 2020 results. As a reminder, this chart reflects the sum of Mylan standalone results and Upjohn carve-out financials for a period of January 1, 2020, to March 31, 2020, adjusted for certain transaction-related items including divested products in connection with the combination. A few key comments on this chart beginning with LOEs as Rajiv mentioned, generic penetration is tracking in line with our expectations and year-on-year Lyrica and Celebrex in Japan are down by $206 million. COVID continues to negatively impact our business as a result of lower volumes across many of key markets, particularly Europe, where we saw pre-COVID surge buying last year and to a lesser extent in the U.S. In China, we saw favorable impacts due to COVID recovery. While we’re still anticipating a gradual recovery beginning in the second half, the recovery is likely to be slower across some emerging markets. Base business erosion was driven by normal price erosion and volume declines in the U.S., Europe, and emerging markets. For the rest of the year, we still forecast erosion about 3% to 4%. We’re off to a good start with new products revenue primarily driven by the European Thrombosis business, which grew versus prior year and additional uptake of Complex Generics and Biosimilars. Lastly, with respect to foreign exchange, it’s important to remember approximately 70% of our business is outside the U.S. In the quarter, the weaker dollar relative to key currencies such as Euro and Chinese RMB provided approximately 5% tailwind compared to our combined adjusted 2020 revenue results. Moving forward, if rates remain at the current level, we expect continued tailwind from foreign exchange consistent with full year guidance, though not at the level realized in quarter one. Moving to Slide 25, which bridges adjusted EBITDA, the year-on-year margin is declining because of the items listed on the bridge. As you will recall from our 2021 financial guidance bridge, we were impacted by lower depreciation and amortization associated with Pfizer TSA, which negatively impacted EBITDA. Turning to Slide 26, free cash flow came in above our expectations driven by strong operating performance, benefits from working capital improvement initiatives, and timing of one-time costs and CapEx. For the quarter, one-time cash costs were approximately $340 million primarily related to integration cost in TSS startup. For quarter two, we expect both to increase over Q1 levels. With respect to cash flow phasing, we expect Q2 cash flow to be significantly reduced versus Q1 and expected to be our lowest for the year. The decline is driven by expected increases in one-time cash cost interest payments, which occur semi-annually in Q2 and Q4, and an increase in capital expenditure. Turning to our balance sheet, strong cash flow allowed us to pay down approximately $1 billion in short-term debt. We anticipate that Q2 short-term debt will increase as a result of June maturity of $2.25 billion final payment of the European Thrombosis business and the quarterly dividend. From a capital deployment standpoint, we declared our first quarterly dividend, which is consistent with our guidance framework. We do not expect the $0.11 per share amount to change for subsequent quarters in 2021, but all future dividend declarations are subject to board approval. Overall, we remain on track with our 2021 free cash flow guidance of $2 billion to $2.3 billion. Moving to Slide 28. As you heard from Michael earlier, we are reaffirming our full-year 2021 guidance ranges based on a strong start we saw in Q1 balanced by expected headwinds for the remainder of the year. In terms of revenue phasing, we expect Q2 2021 to be roughly in line with Q1 2021 due to modest recovery from COVID in Europe, continued strong performance in China offset by expected negative impact of LOEs competition and more normalized EpiPen sales. Going forward, these items will pressure our gross margin to be more in line with our guidance range. As we look out to Q2, we expect SG&A to be in line with Q1 on an absolute basis. On a full-year basis, we expect SG&A to be within our previously indicated range of 20.5% to 21.5%. Given these dynamics, it is likely that Q1 will be the highest adjusted EBITDA quarter. Overall, I’m really pleased with the execution in this quarter in the commitment we delivered against including the initiation of dividends. With that, let me open the call to Q&A. Operator?

Thank you. Our first question comes from the line of Elliot Wilbur of Raymond James.

Thanks, good morning. And first question will be for Sanjeev. Could you just maybe talk a little bit more in detail about some of the working capital initiatives that you’ve undertaken, how they impacted first quarter results, and then maybe just a little bit of color commentary on how working capital trends performed in the quarter versus your expectation? And just a quick clarification, you highlight $315 million in restructuring costs in the deck. And I think the guidance was originally for $450 million for the full year. Just want to make sure that the remaining cash flow drag related to restructuring is only $135 million for the balance of the year. Not sure if there are other items that you should be thinking about, but just some clarification on that item. Thanks.

Elliot, thank you for your question. So there are a couple of questions in that. So, let me take them one by one. So first of all, very pleased with the cash flow generation in the business. Specifically talking about net working capital, there are two things going on. One is the positive side, which is the initiative we’re taking as a company when you bring two companies together, managing our receivables, our payables, and inventory. So that created an upside of roughly about $65 million in this quarter. And that is going to continue to be – we’re going to build on that. So that’s clearly a positive. On the other side of the net working capital from operations we did a little bit have a timing benefit. We were able to accelerate certain collections in Europe in this quarter, which actually helped us and will have an impact on the second quarter, but overall, we’re very pleased and I expect the net working capital improvement initiative to continue to help us for the rest of the year. Coming to the kind of phasing, as I mentioned about on the cash flow, the second quarter, as I said will be significantly lower. Our net working capital requirement for the second quarter will go up, Elliot, because a couple of things are going on, particularly about our debt pay – our interest in debt, it’s about $200 million we’ll be paying in the second quarter, which is only paid in the second and fourth quarter. So there is a quarter-to-quarter variation that is happening. But we are very pleased with that. With regard to your second question about $350 million, as we have in our disclosures, it's a combination of two items. One is the restructuring, which is related to the unabsorbed overhead of the 13 plants that we’ve identified, including Morgantown. Then the second part of that is about the severance that’s across the board based on the initiatives that we’ve taken on the synergy part. So that’s in line with our expectation. And there’s a comment that you made about $400 million that was on the one-time cost as part of the $1.5 billion. So all in line, what you see in this quarter is in line with $1.5 billion. And that is a combination of two items, which are the severance costs and the restructuring costs, which is all part of $1.5 billion.

If I can just add one thing, Elliot, the $350 million is an expense, not cash. So when we’re talking about the cash impact of the restructuring, that phases over time. The charge in the quarter is the $300 million number that you’re referring to.

Thanks.

Operator, next question?

Your next question comes from the line of Umer Raffat of Evercore.

Hi, thanks so much for taking my question. And I just wanted to start by saying this has to be the first time I’ve seen this level of visibility into your product revenue, so appreciate that very much. I had two quick ones. If I may first, the China retail business is up 30% year-over-year. And I’m just trying to understand is that all cash pay, or could payer – if there are payers involved could they find a way to come back and add in some new price corrections down the road? Just trying to figure out how durable the trends are in Lipitor and Norvasc is really what I’m getting at. And one for Rajiv, as well, Rajiv on the Botox biosimilar, I saw that you guys are submitting a briefing package. Does that mean that you’ve adequately validated and characterized and figured out all the process scale-up? Is all of that done at this point? Thank you very much.

Well, let me thank you for your comment on the transparency. That’s exactly what we tried to do. We continue to take your feedback on that. And Rajiv, you could also add both the China and Botox question please?

Umer, thank you. First of all, we are very pleased with our performance in China as you see retail continue to grow, going strength-to-strength. We also see the better than expected management of our hospital business. So, there are two things interplaying into this. Now to your specific question, predominantly retail is cash paid, but there’s a little bit of employer-based sort of healthcare – when you have that healthcare support. That’s a little bit of still where the payers are involved; I can give you exactly what percentages of that, but it is predominantly cash-based. Now, the second question on the Botox – our program is moving along very well, aligned with our partner events. We had laid out, we had gone and met FDA a couple of times; we understand their expectations, we have come to a point where we’re just seeking the agreement on basically both the biosimilarity as well as the clinical program. So, we have enough data now to go back and share with them before we move on. So, we are at a critical stage at this. I’ve seen – I’m very optimistic about this program as we go along.

Okay. Operator, next question, please?

Your next question comes from the line of Nathan Rich of Goldman Sachs.

Hi, good morning. Thanks for the questions. I had two on the competitive dynamics and how they’re playing out relative to your expectations. First, it looks like on the sales walk, the base business erosion of $111 million in the quarter is running kind of well below, I think, the range that you anticipated for the year. I know that the impact may build over the course of the year, but I’d be curious to get your comments on how that flows through the P&L. And then the second question was related to the Lyrica headwind; it looks like $206 million in the quarter that I think if we annualized that would be above the range that you gave back at the Analyst Day. I know it includes Celebrex now, so any additional color you could provide there on in terms of what you’re seeing would be helpful? Thank you.

Thank you, Nathan. I think I’m going to give both questions to Rajiv, and Rajiv I think Lyrica Japan specifically.

Yes. Lyrica, specifically, I think that $206 million is a combination of Lyrica and Celecoxib; 140 of that is Lyrica and about 60-65 of that is the Celecoxib.

Yes, I actually Nathan both are in line. You’re referring to the guidance that we gave at the beginning of the year that only had Lyrica identified and then now we are capturing both. So that both are tracking in line with what we had assumed in our guidance as Rajiv pointed out.

Overall on a base business, just also there was a comment on the base business, underlying business Nate, I can tell you across the geographies whether I start with China or talk about the Developed Markets, North America, Europe, it’s strong, the underlying business is strong, the competitive dynamics are exactly what we had assumed. We see that strength. I think that approach we had adopted to manage this base is a key, and our focus will be to optimize, leverage, and minimize the base. So, as we go along, I think it’s going to further evolve, and we’ll keep you posted on that.

Thank you, Rajiv. And I think what we said from the beginning, we want to build a new kind of healthcare company. One that’s diversified and robust and we really see this playing out this quarter with strength in all four of our regions, all four of our commercial segments, as well as all three of our categories, whether it’s generics, complex generics, and biosimilars or brands. We’re very pleased to see that. Operator, next question, please?

Your next question comes from the line of Chris Schott of JPMorgan.

Great, thanks for the questions. Let me echo Umer’s question – comments earlier about the disclosures being very, very helpful here. Just for me, first on China, any additional clarity or certainty on URP and the impact if implemented? I know, there’s still some uncertainty about that the last update, and I just want to see if you’ve been any additional learnings since then. And the second question I had was just on the developed market, Complex Generics and Biosimilars, and I guess, just trying to make a little bit of flavor here of any products in particular that are particularly driving the growth that we’re seeing, and is this level of growth reasonable going forward? So, I think you are seeing some competitors to some of those products as we think about the next few quarters. So just a little bit more color about how to think about that, that line item evolving as the year progresses. Thanks so much.

Rajiv, you want to start with both of these?

Yes. So first was on China.

Yes, URP.

Given the nature of the implementation, Chris, difficult to give us more visibility, as we learned, as it was evolving. The URP was announced, it was announced that it was going to be implemented in 11 cities, it has obviously changed. Chengdong provision has just implemented recently, and we assume, we had assumed that as we go in the year as we had predicted, five or six other provinces will implement it, perhaps not 11 cities. So, there is a change. So, we have been watching it closely. Given the nature of its implementation, it’s very difficult to give you exact how it’s going to evolve, and what timing, but one thing we know we’ll keep you informed, and the bottom of our China or the trough of our China business will depend upon the extent and the timing of the implementation of the URP. Now, the second question is about the complex and biosimilars category in developed markets. The biosimilars are key contributors to this growth driven by the launch over the last year – year-over-year trastuzumab, pegfilgrastim, Hulio growing, especially in Germany, launching these biosimilars also between Australia and Canada and many of these European markets. So that’s, I would say, the key driver behind this growth in this segment.

Next question, please?

Your next question comes from the line of Balaji Prasad of Barclays.

Hi, good morning, and congratulations on the quarter. Just a couple of multipart questions on the global generics side. So, as I look at Developed Markets generics being down 14%, can you kind of call out the pricing impact, especially in North America and its relative importance to you? And also, as we look at COVID research on India, and you called out that your supply chain is dealing with this, but can you comment on any impact to supply chain from your partner Biocon, which is based in Bangalore, that’s one of the most impacted cities? Thank you.

Thank you. So on the global generics and specifically the U.S. generics question, I’ll ask Rajiv to answer, but just Balaji, just to point out again, that this is 11% of our overall business. And we have one of the strengths we have is that we have such a diversified portfolio now of products, but I think we’re also feeling very well within the category. Rajiv, as you can comment on that please?

Absolutely. The U.S. as Michael said is 11% of our total business, diversified mix between the – even within the generic as we say, left or extended release, as I mentioned, a lot of injectables, a lot of patches and topicals overall pricing trends are very similar to what we had anticipated, the mid-single-digit, if I correct this for COVID. Because if you remember, Balaji, last year, to one was when the COVID impacted, and there was some last 15 days surge buying on some of the products, if I correct it U.S. generics are roughly around 4% decline year-over-year, very much in line with what we had expected, so I end up extensively from our U.S. business point of view. We have healthy inventories in the channel; we have strong customer service levels, and believe our diversified portfolio, our new launches, and steady supply is being appreciated by the customer. So, we feel very good about this 11% part of the business as well. Now, coming back to India, last year was no different. Five months, almost Balaji, if you remember, India was under complete lockdown from March onwards to almost up to July or August; there were four or five months of complete lockdown. We lost about 95%, 96% of our customer service level over the period. Especially regarding to Biocon, we are working very closely with Biocon, and at this point of time where we stand, I don’t see any issue. If I look – if I forward look, we are keeping our eyes to the ground, we are staying close with our customers. We are working closely with the regulators. We’re trying everything to take care of our employees, especially the frontline employees. So, yes, India is important. And at the same point of time, what Mylan legacy, the way the Mylan legacy was dependent upon India, I think our dependence as the new company Viatris is very different now on India. All in all, it’s tough. It’s challenging over there, but we feel good where we stand, from a supply point of view.

Yes, let me underline that. I think the strength of our supply chain, the diversity of supply chain is very robust. That gives a lot of confidence. I think as a general comment on COVID, it's still ongoing; we’re still very much in the midst of it. What we see is from a demand perspective, kind of a divergence in the countries where some countries are clearly improving. China, for example, has been actually headwinds because we compare this quarter to a very low first quarter last year since COVID started there first. We see other regions slowly recovering, mostly due to vaccinations, and then we see countries getting worse, like India or Latin America. So, I think what we can say overall at this point, we’re reaffirming our guidance. We assume a gradual recovery in the second quarter, and we’re confident that the diversity and robustness that we have both on the commercial side as well as supply side, but shows the strength of our model. Next question, please?

Your next question comes from the line of Greg Gilbert of Truist Securities.

Thanks, good day, folks. Just making sure that your comments about potentially updating guidance next quarter come from a position of strength, just in case there’s any investor confusion about why you decided to say it that way. And then Michael, I think it’s a strategic question, perhaps. I think it’s pretty clear to investors why companies like Merck and Pfizer and others decide to divest or separate their legacy businesses to reduce complexity, to focus on innovative activities, et cetera. But how would you describe to investors the value proposition of a story like yours, maybe some angles that the street may not appreciate from your perspective as a longtime operator within one of these companies, not sort of just we need to be estimates and maybe get a value? Rerate that? What are some of those real value propositions from an operational point of view that you sense folks don’t understand? Thank you.

Okay. Greg, thanks for those questions. Let me start with the guidance question and the update for the second quarter. Look, I think it’s very clear that we are very, very pleased with our quarter one results. We come from a position of strength; there’s no other way to say it. I think the results show and really validate, as I said, multiple times, the diversified and robust business model that we have, that can absorb individual headwinds in one part of the business but really jumping and seizing opportunities, where and when we see them. I think you saw us do that in quarter one. You also see the strength of quarter one being in all four of our commercial segments and all three of our categories, whether it’s brand, generics, or complex generics and biosimilars. We’ve been very transparent about what part of that is due to timing, what part of that is due to FX and what part of it is the underlying business performance, but it’s also just one quarter. So, what we’re saying is at this point, we’re reaffirming our guidance for the year. We’re very confident that that applies to revenue, EBITDA, and cash flow. We’re confident that we’re delivering on our commitments. As we would in a regular course of business doing, we’ll look at it again after the second quarter and then update the guidance at that point. That’s what that comment is. On the question you have on Organon, I think it’s very clear that we’re very pleased with this because it’s a real positive for investors to have another company to add as a comparable to our newly created peer set. But we’re obviously focused on running Viatris; we’re 100% focus on that, and we’re excited about the differentiated platform that we have. Let me give you some of the differentiation. One, we have a truly global operating platform, one that has significant scale, significant commercial capabilities, expertise across science and manufacturing, legal IP. Very importantly, we’ve got a broad and diverse product portfolio that includes brands, complex and biosimilars, and generics. That is less important; it is agnostic to any particular therapeutic area, to any particular dosage form, or any particular delivery mechanism. That gives us robustness and opportunities going forward. We’re very proud of the strong R&D that we have; it really positions us well to deliver a broad pipeline of complex and novel products, including the late-stage biosimilars we saw some of the progress we made in the pipeline just this quarter. That’s what I would comment there. We are focused on Viatris, and I think the robustness and diversity of the platform is unique that we have.

Next question comes from the line of David Risinger of Morgan Stanley.

Yes, thanks very much. So, my first question is, could you please discuss organic revenue growth prospects from the 2021 base going into 2022? And then second, could you talk us through your expectations for competition to branded generics ex-U.S. longer term from pure generic companies? Thank you.

Okay, let’s start with organic growth 2021 to 2022 release; Sanjeev you can provide some color on that. I’m not sure I caught the second question, but that may be Rajiv you can...

All right, yes. So David, to your question around the branded generic competition, let me break it into a little Developed Markets, JANZ, and China and give you a little granularity. From the U.S. and Europe, these markets, these products are commoditized, they are steady-teddy; whatever is left is steady-teddy; these are for a reason they are called iconic brands. So, there’s still brand share they manage some of these markets. So, we have seen over the last three, four, five years, there’s been pretty steady business, not much erosion there. Emerging Markets is where still there’s an iconic these brands and there’s a value for these brands; people are looking for these iconic names, and these are the branded generic market for, say, the healthcare environment as the consumerism is growing, as spend on the healthcare costs is growing. We see the opportunity over there; many of these markets are mixed bags, but the growing emerging markets we sometimes call them between us, this is where we see some opportunities over there. You’ve seen at JANZ once you lose – you have a LOE there’s a combination of retaining some of the brand business and the AG business that kicks in for us. We have a pretty effective weapon in terms of authorized JANZ to retain our market share, markets like Japan, especially Japan. You are already seen the value of iconic brands and how much equity they can hold in a retail channel like China. So, for us, we are not very much – overall if I have to say, we are not very much concerned about the competition coming in from generics to this brand. I think we’ve factored in the way we are managing this business is at a very granular level, no one global approach, but a country-by-country approach.

May be the one thing I would like to add to the question on the organic growth and the rhythm is not giving guidance, right; but, I just want to point against the two comments we made already, which is one is what we disclosed today, the $6.2 billion as a flow on EBITDA going forward, I think that should give a lot of confidence. And then the strong cash flow growth that we see because of EBITDA and because of reducing one-time expenses. So that should help a little bit until we give further guidance later in the year. Next question?

Your next question comes from the line of Jason Gerberry of Bank of America.

Hi, guys, thanks for taking my question. So just one follow-up is, should investors look at this year’s revenue as a trough as well; I know that’s one question because revenue was omitted. And then on pipeline, for one key, there’s the call-out on thrombosis. So just wondering about sort of the more true pipeline versus M&A new product. And from like, the truer pipeline products baked into guidance, how comfortable are you that you’re through the regulatory legal gaining factors to really deliver on the full year new product revenue guidance? Thanks.

Okay. Thanks, Jason. What we said is, again, we’re not giving guidance at this point, but the $6.2 billion as a floor, we highly, highly consider them because we know all the levers that we can have. We know the robustness of our business and an EBITDA you can pull many levers. Free cash flow, high confidence again, because we clearly see the growth coming driven by EBITDA and lower one-time costs. On revenue, we got a good understanding of the base erosion that we have in the business. We have a good understanding of the new pipeline revenue we can bring, but if you look at a quarter-on-quarter or even year-on-year, it can be a bit choppy, because of things like COVID, for example, or because of Europe and China timing; if that gets further delayed, that will change a little bit how 2021 over 2022 develops. So we’ll give you an update throughout the year on revenue and again, look for more long-term guidance towards the end of the year on that. Now on the question of thrombosis business, we can break this out, and I’ll ask Rajiv to maybe to break out the number of the pipeline. That the one thing I do want to highlight though is the thrombosis business was always part of the number we gave you for the pipeline. So that’s in line with expectations. I think the important thing that I would like to highlight for this quarter is that we are growing that business on a like-for-like basis. So that shows the strength of what we can bring to the business like this and we take over.

Look, yes, it’s a portfolio approach; $690 million was around the new product portfolio, we called it. There are many – there are about 200-plus products in this. Now, obviously, when you have a portfolio product, some products can be a little bit delayed, some products that perform better than expectations. We remain very confident that we’re going to achieve $690 million, despite we are seeing a little bit of delay in some inspections in India, for example, Biocon called out the bevacizumab, which is Avastin’s biosimilar, but it’s not going to impact us materially from the numbers point of view. Today morning sitting over here, we just got approval in of Avastin biosimilar in Australia. So, approvals are taking in from all over the rest of the world, a little bit here and there, we’ll see something, but it’s going to not come in the way of achieving $690 million new launch revenue for this year.

Thanks, Rajiv. Next question.

Your next question comes from Akash Tewari of Wolfe Research.

Hi, this is Andrew on for Akash, and I just had two if I can. First on China, how much of the revs in the quarter were from FX. And I asked because the pie chart you showed earlier this year kind of implied about $1.75 billion in Chinese revenues this year. And I think like the run rate now is a good bit above that. So, is this just an FX issue? Or does it need to be adjusted downward for additional pressures from like VBP and URP coming in the back half of the year? And then secondly, on EBITDA growth, if I use your starting debt this year, the midpoint of your guide and your debt-paid down guidance, and your leverage goal, and I put those things together. It kind of implies to me that you’re looking at a 2023 EBITDA figure somewhere between like $6.8 billion and $6.9 billion; given you’re going to get another $500 million in synergies over 2022 and 2023, that would imply organic EBITDA growth somewhere in the like $100 million to $200 million range, so pretty flat on that item. Is that the right way to think about it and are there other levers you can pull to change how this would be looking out? Thanks.

Okay, thank you, Andrew. Look on China. Let me ask the question on China – but on EBITDA growth, let me take that first. We’re obviously not given guidance now for 2023. Right, we’re not going to do that. As we will provide further detail later. We said that the 2.5 times leverage is our long-term goal. And that’s our long-term goal post-2023. So that hopefully helps you to model that a little bit. On China, clearly, we do still expect your peer to come in the second half of the year. So take that into account for the rhythm of the numbers. Sanjeev, maybe you can give some color on the FX column.

Right, right. So, if you look at Slide 14 that we had as part of our presentation, so that kind of breaks it out between FX and the operational growth, what’s going on? So, I think on both sides, you’re absolutely right. FX is a tailwind in China. The Chinese RMB, which was in the RMB 7 to $1 is roughly at $6.5 billion this time. So there is obviously a tailwind coming from the FX, but operationally as well. Greater China is done well. Part of it is driven by the fact that last year, we were impacted by COVID in a big way in products like Viagra, we’re doing better this quarter. But again operationally, as Rajiv pointed out in his comment, we’re doing well, so that’s the answer to the China question. And then things will normalize as COVID impacts – COVID recovery happens in case of China.

Thank you, Sanjeev. Next question, please.

Your final question comes from the line of Ronny Gal of Bernstein.

Good morning, everybody and appreciate you filling me in. Two questions if you don’t mind product specific. First about the interchangeability for Glargine and Aspart. So first, I will obviously be quite an achievement being the first biosimilars approved as interchangeable. I guess the question I have is about the commercial levers that you can play here. It seems that the payer market is somewhat blocked by the competitors at least that’s what they’re suggesting. I was wondering if you do have some levers in the channel that interchangeability gives you that will allow you to leverage those products and should we expect that in 2021? Or is this more for 2022, 2023 contributor? And second, regarding botulinum toxin biosimilar, the requirements in the guidance talk about characterizing the quarter structure and the post-translational modifications across multiple batches, which seems to be very hard in the case of botulinum toxin. I was kind of wondering if you actually just met those? Or is the FDA simply established more functional guidelines for the botulinum toxin just giving the very small amount of product in every sample? Thank you.

Rajiv?

Yes. From an interchangeability perspective, we have been closely working with the FDA on Glargine and have a clear understanding of our position. By our goal date in July, we anticipate having this resolved and achieving the first interchangeable Glargine for both vials. You are correct about the challenges we face with peer pricing, but in discussions with our customers, we view this as a chance to relaunch this product. Once we establish interchangeability with Aspart, we see this as an opportunity to reposition ourselves in the market where we have been gradually increasing our share, currently around 2.5%. However, we aim to improve further. This will provide us the flexibility to approach this product in a new way and effectively relaunch it. Regarding Botox, you are right that the FDA's guidance and perspective are evolving as we continue to share data with them. The interactions with the FDA involve discussions about scientific challenges and what is feasible. At this moment, we are feeling optimistic about the early scientific data we have received and the positive feedback from the FDA.

Thank you, Rajiv. And I think we’re a little bit over time, but we want to have time for one more question, please. Operator?

Your final question will come from the line of Gary Nachman of BMO Capital Markets.

Okay, thanks for getting me in. Good morning. Michael, what do you expect the pace will be securing partnerships in various regions for the global healthcare gateway? Are there already a lot of discussions ongoing with different parties? How long before you really start to execute on that? And in what regions do you think would come first? And then secondly, the $1.5 billion of cost to achieve synergies is there a chance it’ll come below that this year? And how much will those costs come down next year? Just want to get a sense of how everything is going on that front and the impact to cash flow if you were conservative or if that’s really the accurate assessment at this point? Thanks.

Thank you, Gary. So let me say on the global healthcare gateway, obviously, it is a very important topic for us; we’re constantly looking for opportunities to create value for patients, partners, and especially for our shareholders. We’re going to always apply our disciplined investment criteria and be very, very strict on due diligence on that. So, you can absolutely expect us to be very active in the space, but consistent with our capital allocation priorities. In terms of focus areas, I want to maybe highlight that one is established brands within our therapeutic categories or established channels that we have that are synergistic to that. You’ve seen what we can do with this from the thrombosis franchise, for example, where we take it and improve on it. Biosimilars are clearly our focus area for us, China is a focus area for us, and then anything that helps us go up the value chain with more differentiation and longer tails. We’re not – we’re looking for long-term sustainable kind of revenue in these areas. So that’s, I would say these are the areas that I want to focus on. And then on the $1.5 billion, Sanjeev, if you could take that question?

Yes, sure. So obviously, we are monitoring and managing the one-time spent very closely in this quarter, as I mentioned in my prepared remarks, we had $340 million. So at this point in time, where we are – I see we will be in line with our expectation of $1.5 billion; clearly, the other thing important to note is quarter-to-quarter, there’s going to be variability. As I said, quarter two the one-time cost is going to be higher because of a lot of the tax and legal settlements that are happening in quarter two, but overall for the full year, we expect that to be around $1.5 billion. Going forward, again, not giving the guidance, and I think the simple way to think about this is by the end of the third year, I expect the $1.5 billion to be down significantly to the level that legacy Mylan used to be, which was, I think, in 2017, 2018, used to be about $500 million. So, as you can see, the trajectory is going to come down significantly next year. Obviously, when we provide the 2022 guidance, we’ll let you know about the exact amount.

Thank you, Sanjeev. So unfortunately, we’re overtime. But let me just summarize. You’ve seen our first quarter results. They’re very strong. We’re very confident and proud of them. They validate everything, the strengths of the diversified and robustness business model that we have. And that differentiates us as a company. You’ve seen us meeting our financial commitments; we will continue to do that, including declaring a dividends, paying down our debt, and on track to deliver on our synergies. We are reaffirming our full year 2021 guidance. As we said after the end of Q2, we’re going to look at that again and reassess whether we would update that guidance. We continue to remain confident that 2021 is our trough year. We gave a definition of that; that definition is $6.2 billion and EBITDA as our floor going forward. With that, I want to thank you for all the questions and look forward to continued discussion. Thank you.

Thank you. This concludes today’s Viatris first quarter 2021 earnings conference call and webcast. Please disconnect your lines at this time. And have a wonderful day.